Overview
- Susan B. Anthony Pro-Life America’s Marjorie Dannenfelser and Live Action’s Lila Rose called for Commissioner Marty Makary’s removal and pressed for a return to in‑person dispensing of mifepristone.
- Bloomberg, citing unnamed sources, reported Makary asked to delay the safety review’s results until after the next midterm elections.
- HHS spokespeople rejected claims of political delay as baseless, and the White House said Makary is ensuring a “Gold Standard Science” study of the drug.
- In an interview, Makary said the FDA is in the “data acquisition” phase of a robust review he oversees, gave no timeline, and pledged to make the results public.
- The dispute follows an EPPC claims analysis reporting roughly 11% complications versus medical groups’ filings citing serious adverse events under 0.32%, with tensions heightened by the FDA’s October approval of a second generic.